investor harm

Class action lawsuit filed against $APO over alleged false statements regarding Jeffrey Epstein connections and undisclosed reputational risks.

Class action lawsuit filed against Babcock & Wilcox alleging executives made false statements and failed to disclose largest shareholder conflicts in Applied Digital power contract. Eligible investors sought from Nov 2025 to March 2026 purchase period.

Class action lawsuit filed against $ATARA alleging executives misled investors about manufacturing issues and study deficiencies affecting tabelecleucel FDA approval prospects.

Class action lawsuit filed against $CHOW alleging securities fraud, market manipulation via social media misinformation, and undisclosed trading suspension risks.

Class action lawsuit filed against Grocery Outlet ($GO) alleging securities fraud, false financial statements, and unsustainable expansion strategy from August 2025-March 2026.

Class action lawsuit filed against Gossamer Bio alleging material misstatements regarding Phase 3 PROSERA study results and hidden design flaws at Latin American test sites.

Class action filed against Navan alleging IPO prospectus contained false statements regarding sales and marketing expenses needed for revenue growth.

Class action lawsuit filed against monday.com alleging material misstatements on revenue expansion, growth prospects, and sales cycles from September 2025 to February 2026.

PSIX sued for allegedly misleading investors about data center sales prospects and understating manufacturing costs. Class action covers May 2025–March 2026 purchases.

Class action lawsuit filed against Alight alleges executives made false statements on growth targets and capital returns. Investors who bought shares November 2024-February 2026 may be eligible; lead plaintiff deadline May 15, 2026.

Boston Scientific faces class action lawsuit alleging material misstatements about U.S. electrophysiology segment. Investors from July 2025-February 2026 may have claims; May 4, 2026 deadline to apply as lead plaintiff.

Trip.com faces class action lawsuit alleging failure to disclose regulatory risks tied to monopolistic practices. Investors have until May 11, 2026 to join.

Class action lawsuit filed against $CIGL alleging false statements, social media fraud, and insider share dumping between April-July 2025.

Class action lawsuit filed against Aldeyra Therapeutics alleging false statements about reproxalap clinical trial results, covering investors from November 2023 through March 2026.

Class action lawsuit filed against $STLA alleging materially false statements on earnings forecasts and electrification strategy between February 2025 and February 2026.

Class action lawsuit filed against Coty Inc. alleging executives made false statements about growth prospects and concealed segment challenges during November 2025-February 2026 period.

Class action lawsuit filed against Lakeland Industries for allegedly making false statements about business operations and overstating division performance between December 2023 and December 2025.

Class action lawsuit filed against Lufax Holding Ltd alleging securities fraud and inadequate internal controls from April 2023 through January 2025.

Class action lawsuit filed against Corcept Therapeutics alleging executives made false statements about relacorilant's clinical strength and FDA approval prospects.

Class action lawsuit filed against $MDPC alleging executives overstated book-to-bill ratio at approximately 1.15 despite contrary internal data from April 2025 to February 2026.